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ABSTRACT 
Study Objectives: To determine the effect of self-reported clinical diagnosis of Obstructive 
Sleep Apnea (OSA) on longitudinal changes in brain amyloid-PET and CSF-biomarkers (Aβ42, 
T-tau and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI) and Alzheimer’s 
Disease (AD) elderly. 
Methods: Longitudinal study with mean follow-up time of 2.52±0.51 years. Data was obtained 
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Participants included 
516 NL, 798 MCI and 325 AD elderly. Main Outcomes were annual rate-of-change in brain 
amyloid-burden (i.e. longitudinal increases in florbetapir-PET uptake or decreases in CSF-Aβ42 
levels); and tau-protein aggregation (i.e. longitudinal increases in CSF total-tau (T-tau) and 
phosphorylated-tau (P-tau)). Adjusted multi-level mixed effects linear regression models with 
randomly varying intercepts and slopes was used to test whether the rate-of-biomarker-change 
differed between participants with and without OSA.   
Results:  In NL and MCI groups, OSA+ subjects experienced faster annual increase in 
florbetapir uptake (B=.06, 95% CI .02, .11 and B=.08, 95% CI .05, .12 respectively) and 
decrease in CSF-Aβ42 levels (B=-2.71, 95% CI -3.11, -2.35 and B=-2.62, 95% CI -3.23, -2.03, 
respectively); as well as increases in CSF T-tau (B=3.68, 95% CI 3.31, 4.07 and B=2.21, 95% CI 
1.58, 2.86, respectively) and P-tau (B=1.221, 95% CI, 1.02, 1.42 and, B=1.74, 95% CI 1.22, 
2.27, respectively); compared to OSA- participants. No significant variations in the biomarker 
changes over time were seen in the AD group. 
Conclusions: In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed 
to test if OSA treatment may affect the progression of cognitive impairment due to AD. 
Key Words: Obstructive sleep apnea; Alzheimer’s disease; Longitudinal study, CSF-
biomarkers; Brain amyloid-PET; Aβ42; T-tau; and P-tau 
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STATEMENT OF SIGNIFICANCE 
Recent studies show that obstructive sleep apnea (OSA) is associated with increased Alzheimer’s 
disease (AD) risk. This study adds to the literature by providing evidence that OSA is related to 
longitudinal increases in amyloid and tau burden in cognitively normal and mild cognitive 
impairment (MCI) OSA patients when compared to healthy controls. These novel findings are 
directly relevant to the emerging literature examining for evidence of a causal relationship 
between OSA and AD, and are of interest to further understand the various possible mechanistic 
links that explain this relationship. More importantly, it suggests that clinical interventions aimed 
to treat OSA in the elderly may slow the progression of cognitive impairment due to AD.   
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INTRODUCTION 
Intermittent hypoxia and sleep fragmentation have been implicated as possible 
mechanistic links in a causal pathway between obstructive sleep apnea (OSA) and Alzheimer’s 
disease (AD).
1-4
 Recent cross-sectional studies have demonstrated associations between OSA 
and AD-biomarkers (i.e. brain amyloid-PET and CSF-biomarkers (Aβ42, T-tau and P-tau)) in 
both cognitively normal (NL) and mild cognitive impairment (MCI) elderly.
5-7
 Clearly 
establishing whether OSA individuals are at heightened risk to develop AD is critical for 
preventing AD.  Positron emission tomography (PET) amyloid-tracer uptake and decreases in 
cerebrospinal fluid (CSF) amyloid-beta42 (Aβ42) levels are robust predictors of amyloid burden 
as well as of future development of AD.
8,9
  Significant increases in CSF P-tau and CSFT-tau are 
also documented in AD patients compared with controls.
10
 An important question is whether 
OSA-AD association is related to changes in AD neuropathology over time. Recently, our group 
demonstrated that objectively measured OSA was associated with markers of increased amyloid 
burden over a 2-year follow-up in the NYU cohort which consists exclusively of community-
dwelling healthy cognitively normal elderly. In this study, we examined self-reported clinical 
diagnosis of OSA’s association with longitudinal changes of brain amyloid-burden and tau-
protein aggregation in a sample of cognitively normal (NL), mild cognitive impairment (MCI) 
and Alzheimer’s Disease (AD) elderly in the larger Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) cohort, to provide additional evidence for a possible causal relationship between OSA 
and AD.  
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METHODS 
Data were obtained from the ADNI database (adni.loni.usc.edu). ADNI was launched in 
2003 as a public-private partnership, led by Michael W. Weiner, MD. The primary goal of ADNI 
has been to test whether serial MRI, PET, other biological markers, as well as clinical and 
neuropsychological assessments can be combined to measure the progression of MCI and early 
AD. Thus far, ADNI has recruited over 2,000 adults aged 55-90, consisting of NL, MCI, and 
early AD. Follow-up for CSF sampling and PET typically occurs every 1-2 years. 
Standard Protocol Approvals, Registrations and Patient Consent 
The Institutional Review Board at each of the ADNI participating centers approved the 
ADNI study. Written informed consent was obtained from all patients participating in ADNI. 
ADNI inclusion and exclusion criteria are detailed elsewhere (http://adni.loni.ucla.edu/wp-
content/uploads/ 2010/09/ADNI_GeneralProceduresManual.pdf). 
Study Participants 
Participant data used for this study were based on medical history obtained from the 
ADNI database on December 2016. This study included 1,639 participants: 516 NL, 798 MCI 
and 325 AD. Subjects missing biomarker data were excluded. Subjects with pre-existing co-
morbid sleep disorders other than OSA, and those with body mass index (BMI) change greater 
than 5 between visits, were further excluded, since both could modify group allocation (i.e. 
OSA+ vs. OSA-).
11
 Other exclusions included previous OSA surgery and having a reversible 
diagnosis (i.e. had a MCI or AD diagnosis at any time point but a NL diagnosis or MCI 
diagnosis, respectively, at their last visit), thereby allowing us to exclude reversible conditions 
and unspecified diagnoses.  
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OSA diagnosis 
Presence or absence of OSA was based on self-reported clinical diagnosis of OSA 
(variable name: MHDESC) during a clinical interview. Patients with reported “sleep apnea”, 
“sleep disordered breathing”, “OSA” or “SDB” were labeled OSA+ and the remaining 
participants were considered OSA−.  To ensure that patients were allocated into the correct 
groups, three physicians (R.O., S.A. and O.B.) reviewed medical history clinical notes from the 
ADNI download, for group allocation. 
NL, MCI and AD Diagnosis 
ADNI criteria for subject classification are described elsewhere.
12
 NL and MCI subjects 
scored between 24-30 on the Mini-Mental State Examination (MMSE) while AD subjects scored 
between 20-26. MCI and AD participants had global Clinical Dementia Rating (CDR) scores of 
0.5 and 1, respectively. The diagnosis of AD was made using established clinical criteria.
13
   
Florbetapir-PET Imaging Acquisition and Interpretation  
ADNI florbetapir summary data was uploaded to the Laboratory of Neuroimaging 
(LONI) by the University of California at Berkeley.
14,15
 For more information on the methods 
see: https://adni.loni.usc.edu/wp-
content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf, 
http://adni.loni.usc.edu/updated-florbetapir-av-45-pet-analysis-results/. Briefly, native-space 
segmented and parcellated magnetic resonance imaging (MRI) scan with Freesurfer (version 
5.3.0) was used for each subject to define cortical grey matter regions of interest (frontal, 
anterior/posterior cingulate, lateral parietal, lateral temporal) that make up a summary cortical 
region of interests (ROI). Five reference regions (cerebellar grey matter, whole cerebellum, 
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brainstem/pons, eroded subcortical white matter, and a composite reference region) were 
defined. Each florbetapir scan was then matched to the corresponding MRI and the mean 
florbetapir uptake within the cortical and reference regions is calculated. The baseline MRI was 
used to define regions for all subsequent florbetapir scans. Image data are available at 3 levels of 
preprocessing (raw, unsmoothed, and smoothed) as described online at 
http://adni.loni.usc.edu/data-samples/mri/. Calculation of Florbetapir standardized uptake value 
ratios (SUVRs) were done by obtaining means across the 4 cortical regions and dividing this 
cortical summary ROI by one of the five reference regions. Cortical ROI selection and reference 
region is predicated on the goals of the analysis. Two summary SUVRs were provided. The first 
is the cortical summary ROI divided by the whole cerebellum reference region 
(SUMMARYSUVR_WHOLECEREBNORM), which as recommended we used for cross-
sectional florbetapir analyses. The second is the cortical summary ROI divided by a composite 
reference region (SUMMARYSUVR_COMPOSITE_REFNORM), which as recommended we 
used for our longitudinal florbetapir analyses. 
Cerebrospinal Fluid Methods (CSF) 
CSF bio-specimen data collection details can be found at http://adni.loni.usc.edu/data-
samples/biospecimen-data/. Briefly, Aβ42, t-tau and p-tau181 were measured from CSF that was 
collected at each ADNI site, and transferred into polypropylene transfer tubes followed by 
freezing on dry ice within 1 h after collection and shipped overnight to the ADNI Biomarker 
Core laboratory at the University of Pennsylvania Medical Centre on dry ice. A standardized 
protocol was implemented to quantify biomarker concentrations in each of the CSF baseline 
aliquots using a multiplex xMAP Luminex platform (Luminex Corp, Austin,TX) with 
Innogenetics (INNO-BIA AlzBio3, Ghent, Belgium; for research use only reagents) 
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immunoassay kit-based reagents, validated in Vanderstichele et al.
16
 and Shaw et al.
17
 Further 
details can be found at (http://www.adni-info.org/index.php). 
Covariates/potential confounders 
 As our study tried to answer an etiological question, we employed a broad selection of 
covariates based on published literature.
18,19
 Covariates were selected a priori and included 
factors that might be more common in cases with OSA and that might contribute to either Aβ-
pathology (CSF Aβ42 and Florbetapir PET) or neurodegeneration (CSF T-tau), including age, 
sex, BMI, education, CPAP-use, ApoE4 status, alcohol intake, baseline biomarker data, history 
of respiratory disease, hypertension, diabetes and history of cardiovascular disease (e.g. 
including ischemic heart disease, heart failure, and stroke/TIA), as well as history of traumatic 
brain injury.  
Data analyses  
All analyses were conducted separately for each clinical group (i.e. NL, MCI, and AD). 
Cross-sectional analyses of baseline AD-biomarker levels by OSA status were conducted using 
generalized linear methods.  
Multivariate analysis of variance (MANOVA) was conducted to test differences in time-
trend, groups (OSA+ vs. OSA-) and time points. To test differences in time-trend, baseline 
biomarker data was subtracted from data at each time point.  
ADNI data is unbalanced with unequal numbers of measurement for each participant. We 
therefore used multi-level mixed effects linear regression models with normal errors,
20
 
examining the relationship between OSA and the rate-of-change in AD biomarkers. This allowed 
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the incorporation of all  available information  and possibly reduced bias resulting from using 
only the complete cases.
21
  
To determine the specific type of modeling, we examined profile plots for the biomarker 
levels over time by OSA status, using both the original dataset and within-subject residuals. We 
also examined trajectory plots obtained by subtracting the baseline measurement from the 
original measurements (i.e. dij= Yij−Yi1) and examined plots of mean and variance of the 
biomarkers at each time point by OSA status. Further, using the slopes as summary statistics, we 
conducted different formal tests to compare groups. Our assumption was that the rate-of-change 
of biomarker data is approximately linear over time. Thus, we used a parametric model with time 
as a continuous variable. We fitted the models with randomly varying intercepts and slopes and 
allowed them to depend on exposure group (i.e., OSA status). Based on the findings, we then 
fitted a random coefficients model to analyze the relationship between OSA status and time 
using unstructured covariance. To find a parsimonious covariance structure, we fitted many 
different covariance models and conducted a likelihood ratio test of each nested model using 
information criteria for non-nested models. Finally, using the unstructured, independence 
covariance model (i.e., the preferred covariance structure), we tested whether the rate-of-change 
in biomarkers differed between OSA groups. Final models were adjusted for age, sex, BMI, 
education, CPAP-use, ApoE4 status, alcohol intake, baseline biomarker data, history of 
respiratory disease, hypertension, diabetes and history of cardiovascular disease (e.g. including 
ischemic heart disease, heart failure, and stroke/TIA), and history of traumatic brain injury. 
  Adjustment for the extensive list of covariates had little impact on the estimates. The 
age and sex only-adjusted model and the extensively-adjusted model showed similar results, 
indicating little to no risk of bias due to over-adjustment. Sensitivity analysis removing CPAP-
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users (NL: n=10; MCI: n=16; AD: n=9) from OSA+ participants had also a negligible impact on 
the estimates (e.g. NL florbetapir estimate of .06 changed to .08).  Statistical analyses were 
performed using SAS (version 9.4; SAS Institute Inc., Cary, NC).  
 These analyses allowed us to examine whether significant variation between OSA 
subjects in mean AD biomarker level at baseline (intercept) existed, as well as whether 
significant variation in the change in AD biomarker level over time (slope) occurred. 
Furthermore, the covariance between the baseline AD biomarker level (intercept) and AD 
biomarker change over time indicated whether OSA+ or OSA- subjects had experienced a faster 
increase or decrease in AD biomarker level over time (significant slope). It also allowed for 
assessment of significant differences in the rate of change in AD biomarker level between OSA+ 
and OSA- patient groups over time.  
Data Availability Statement 
 Authors state that anonymized data will be shared by request from any qualified 
investigator. 
RESULTS 
Demographic and Clinical Characteristics 
Figure 1 shows the stepwise exclusion process for NL, MCI and AD participants used in 
the study. Table 1 shows the demographic and clinical characteristics of study participants at 
baseline. Overall, the mean ages of OSA+ and OSA- were 72.3±7.1 and 73.9±7.3 years, 
respectively. Female participants represented 49%, 40% and 37% of the NL, MCI and AD 
groups, respectively. Six percent were OSA+ in the NL group, while 13% and 7% were OSA+ in 
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the MCI and AD groups. Participants differed markedly in ApoE4 status with 28%, 51% and 
66% being ApoE4 positive in the NL, MCI and AD groups. NL, MCI and AD participants were 
similar in age, education, BMI, and the three medical conditions across groups. Mean follow up 
time was 2.52±0.51 years.  
Baseline AD Biomarker levels by clinical group and OSA status  
Table 1 and Supplementary Figures 1a-c show raw baseline CSF Aβ42, T-tau and P-tau 
levels, and florbetapir PET uptake in NL, MCI and AD groups, by OSA status. There were 
significant differences in CSF Aβ42 levels for both MCI (F=4.37, p=.04), and AD (F=6.89, 
p<.01) groups respectively (Figure 1), with OSA+ participants having significantly higher levels 
at baseline for the MCI group. Significant difference in T-tau levels was seen for the MCI 
patients (F=5.08, p=.02) (Figure 1) with OSA+ individuals having significantly lower levels. 
These differences remained after controlling for covariates, but the magnitude of the differences 
was small. For florbetapir values there were significant differences between OSA groups for both 
NL and MCI participants (F=5.53, F=5.15, p ≤.02 for all respectively) (Figure 1) with OSA+ 
participants having significantly lower florbetapir values. However, after controlling for age, sex, 
BMI, education, CPAP use, ApoE4 status, and other medical conditions, these differences in 
florbetapir values were no longer significant. For P-tau levels, no significant difference was seen 
across all groups in the uncontrolled and controlled analyses.  
Differences in Time Trend, Groups (OSA+ versus OSA-) And Time-points   
Table 2, Figures 2 - 4, and Supplementary Figures 2a-c show MANOVA results testing 
the differences in the mean change in AD-biomarker values over time, based on OSA status. The 
Pillai’s trace test values presented examines time-point*OSA effect and provides the exact F 
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statistics for the time trend of mean-change in AD biomarker across OSA groups. The time-point 
effect provides the exact F statistics for the mean change (increase or decrease) in Alzheimer's 
disease biomarker over time. Other stats interpretations can be seen in the Table 2 footnote. 
In NL and MCI participants, the time trend of mean change in florbetapir PET value 
indicated the change was not parallel across groups (Pillai’s trace test, p=.01 for all). Across all 
subjects, mean change in florbetapir uptake increased significantly over time (Pillai’s trace test, 
p<.001 for all).  There were significant differences in mean change in florbetapir values across 
the OSA groups when the previous time-point was compared to the next (p≤.01 for all).  
In AD participants, the only significant finding was that the mean change in florbetapir 
uptake increased over time across all subjects (Pillai’s trace test, p<.001). 
In NL and MCI participants, the time trend of mean change in CSF Aβ42, T-tau and P-
tau values indicated the change was not parallel across groups (Pillai’s trace test, p≤.05 for all). 
Across all subjects, mean change in CSF Aβ42 values decreased while T-tau and P-tau values 
increased over time (Pillai’s trace test, p<.001 for all).  There were significant differences in 
mean change in CSF Aβ42, and T-tau values across the OSA groups when the previous time-
point was compared to the next (p≤.01 for all).  For P-Tau, significant differences were only seen 
when timepoint_1 (year 2) was compared to timepoint_0 (year 1) (p<.001). 
In AD participants, the time trend of mean change in CSF T-tau indicated the change was 
not parallel across groups (Pillai’s trace test, p≤.01).  Across all subjects, mean change in CSF 
Aβ42 values decreased while P-tau values increased significantly over time (Pillai’s trace test, p: 
<.001 for all).  There were significant differences in mean change in T-tau values across the OSA 
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groups only when timepoint_1 (year 2) was compared to timepoint_0 (year 1) (p <.001).  No 
significant differences were seen for CSF Aβ42.  
Rate-of-change in AD Biomarker by OSA status 
Table 3 reports the between-subjects variation and covariance parameter estimates in AD 
biomarker levels over time by OSA group.  
In both NL and MCI participants at baseline, OSA+ participants had lower levels of CSF 
T-tau, CSF P-tau and brain Florbetapir values and higher CSF- Aβ42 levels, compared to OSA- 
subjects (Table 1). Interpretation of the covariance parameters is such that, if the signs of these 
estimates are negative, they show that persons with higher baseline values tend to have less rates 
of change over time. For example, in NL participants, for the flobertapir values, the covariance 
parameter estimate of -.06 (-.09, -.04) indicates that OSA- participants who had a higher baseline 
tended to have slower rates of amyloid deposition over time (Figure 2). The covariance 
parameter estimate for CSF Aβ42 of 3.93 (3.56, 4.31) indicates that OSA+ who had higher 
baseline values tended to have higher rates of changes over time (in this case decline because of 
the negative slope) 
In NL participants, there was significant variation by OSA status in the annual change in 
brain florbetapir uptake (mean SUVR; B=0.06, p<.0001). In MCI participants, there was also 
significant variation by OSA status in the annual change in florbetapir values (mean SUVR; 
B=0.08, p<.0001). The covariance between the baseline florbetapir uptake and the annual 
florbetapir value change was -.06, indicating that OSA+ subjects experienced faster increase in 
amyloid deposition over time (p<.0001) when compared to OSA- (Figure 3 and supplementary 
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2b).  No significant variation in the change in brain florbetapir-PET volumes by OSA status was 
seen in the AD group (Table 3 and Figure 4). 
For the NL and MCI groups, there was significant variation in the annual change in CSF 
Aβ42 by OSA status (mean CSF levels; B=-2.708, mean CSF levels; B =-2.264, p<.0001 for all 
respectively).  Significant differences in the annual change in T-tau and P-tau levels over time 
were also observed in both groups. Covariance parameters between the baseline CSF Aβ42, T-
tau and P-tau level change over time indicated that OSA+ subjects experienced a faster 
longitudinal decrease in CSF Aβ42 and faster longitudinal increases in T-tau and P-tau levels 
(p<.0001 for all) compared to OSA- participants, in both the NL and MCI groups (Table 3 and 
Figures 2 - 4). No significant variations in the change in CSF Aβ42, T-tau and P-tau levels over 
time were seen for the AD group (Table 3). 
DISCUSSION 
The major objective of this study was to examine the association of OSA and longitudinal 
changes in brain amyloid-PET deposition and CSF biomarkers.  There were significant 
differences in the annual rate-of-change in florbetapir uptake as well as CSF Aβ42, T-tau and P-
tau levels over the follow-up period for the NL and MCI groups, with OSA+ subjects 
experiencing significantly faster increase in brain amyloid load (as measured by increases in 
florbetapir uptake and decreases in CSF Aβ42 levels) and tau aggregates (as measured by 
increases in CSF T-tau and P-tau levels). The direction of these longitudinal changes is in 
accordance with growing evidence described below showing a link between disturbed sleep, 
OSA and AD pathogenesis. In a cross-sectional study, Spira et al.
22
 found that MCI individuals 
with higher apnea-hypopnea and oxygen desaturation indices demonstrated higher amyloid 
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deposition on Pittsburgh compound B (PiB)-PET uptake globally and regionally in the 
precuneus. Recently, Yun et al.
7
 found that OSA patients had a higher amyloid burden in the 
right posterior cingulate gyrus and right temporal cortex relative to controls, suggesting possible 
contribution of OSA. In a population of NL individuals, Liguori et al.
5
 compared CSF 
biomarkers in OSA+ vs. OSA+ treated with CPAP as well as OSA- controls. Findings 
demonstrated lower CSF Aβ42 and higher T-tau/Aβ42 ratio in OSA+ compared to CPAP treated 
and OSA- control subjects. We also have recently documented that OSA severity is associated 
with increased amyloid burden (measured as longitudinal decreases in CSF Aβ42 and increases 
in PiB uptake) over a 2-year follow-up in community-dwelling NL-elderly.
23
  
Possible mechanisms responsible for these findings include intermittent hypoxia, sleep 
fragmentation and intrathoracic pressure swings (see Figure 5).  Studies of cerebral ischemia 
suggest that both acute and intermittent hypoxia may promote Aβ accumulation,2,4,24-26 possibly 
mediated by hypertension,
27
  cardiovascular disease,
28
 diabetes,
29
  chronic inflammation,
30
 and 
oxidative stress.
31,32
 Sleep fragmentation, arousals and circadian rhythm disruption have also 
been shown to increase the risk of developing MCI/AD,
1,33
 possibly through disruption of slow 
wave sleep (SWS).
34,35
  Findings from a recent prospective study on subjects from the 
Framingham Heart Study cohort; suggest that OSA-related REM disruption may also contribute 
to this association.
36
 Other possible mechanisms include elevated intrathoracic, intracranial 
pressures and/or increased venous pressure, which have been hypothesized to acutely and 
repetitively impede the circulation of brain metabolites from the interstitial fluid (ISF) into the 
CSF through the glymphatic system, leading to increases in Aβ accumulation.24,31,32,37 Lastly, 
depression has been reported as both a consequence of OSA and an AD risk factor and may also 
contribute to this association.
38
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Intriguingly, at baseline, our data showed that OSA+ patients had significantly higher 
CSF Aβ42 in MCIs, lower florbetapir uptake in both NL and MCIs, and lower T-tau levels in 
MCIs, compared to OSA- subjects. A possible concern here is a regression toward the mean, 
since the OSA+ group starts with significantly lower values of amyloid load in some of the 
biomarkers used. However, there are two factors worth addressing in this regard. First, the 
absolute difference in these levels between groups was numerically quite small (e.g., in NL 
subjects, the difference in the median CSF Aβ42 levels was 17 pg/mL). Second, the longitudinal 
analyses examined the “rate-of-change” as an outcome and not the mean levels of the AD-
biomarkers. The longitudinal mean beta statistics presented refer to the mean change 
incorporating within and between group data. In addition, what we examined was the slope 
statistics incorporating the effects of time, which looked at the rate-of-change for each individual 
between OSA groups.  Furthermore, one could expect faster progression of amyloid deposition 
in the NL group that has already higher amyloid burden at baseline,
39,40
 which would have driven 
our findings toward the null. Possible explanations for the reduced baseline AD biomarker 
presentation in the OSA+ group include; first, if OSA accelerates AD pathology build-up this 
may simply be a sign of selection (survival) bias as most OSA+ will have transitioned to MCI or 
AD and only those with very low AD pathology burden at disease onset would remain as 
cognitively normal. Second, particularly in those with MCI, is the presence of increased vascular 
risk in this group (i.e. higher rates of diabetes and obesity) (Table 1), as onset of cognitive 
impairment is likely to occur at a lower severity of Alzheimer lesions in individuals with more 
vascular pathology.
41
 Notably, after age-stratification (55 – 73.8, and 74 - 92) based on age 
distribution (we categorized based on the 50
th
 percentile), compared to OSA- individuals, OSA+ 
individuals in the 55 – 73.8 years old category were more likely to have higher vascular burden 
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(i.e. composite score for BMI, hypertension, diabetes and cardiovascular disease), higher CSF 
Aβ42 in MCIs, lower florbetapir uptake in both NL and MCIs, and lower T-tau levels in MCIs 
(see supplementary Table 1). In addition, among ages 74 years and above, OSA+ participants 
had a worse AD biomarker presentation (i.e. lower CSF Aβ42 in MCIs, higher florbetapir uptake 
in both NL and MCIs, and higher T-tau levels in MCIs) at baseline. These findings suggest that 
the younger population especially in the OSA+ with higher vascular burden were driving the 
noted differences at baseline between OSA+ vs. OSA- groups. Third, specifically for CSF Aβ42; 
slow wave sleep (SWS) occurring during non-rapid eye movement (NREM) sleep, a known Aβ 
modulator, 
35,42,43
 may be responsible. OSA is associated with reduced SWS.
44
 Sleep is involved 
in the clearance of Aβ,35 and fragmented SWS limits brain Aβ clearance, thereby leaving higher 
levels that reflect in the CSF.
45,46
  At cross-section, disrupted SWS has been shown to be 
associated with higher CSF Aβ42 in middle-aged24,47 and older adults.34 Fourth, in both the NL 
and MCI groups, OSA- had more APOE4 positive participants, which is known to confer higher 
risk and worse AD biomarker burden.
48
 It is important to note that as stated above (see Results 
section: Baseline AD Biomarker levels by clinical group and OSA status), after controlling for 
age, sex, BMI, education, CPAP use, ApoE4 status, and other medical conditions, the differences 
in florbetapir values w re no longer significant. For P-tau levels, no significant difference was 
seen across all groups in the uncontrolled and controlled analyses. In other words, these 
differences are numerically but not statistically different from each other, and where they were 
“statistically” significantly different, it is not clear that they are clinically meaningfully different. 
Our findings in a cohort of self-reported OSA patients suggest that untreated OSA can 
predispose to neurodegenerative processes in the long-term by gradually weakening brain 
structure and altering its functioning.
49,50
 This hypothesis would be consistent with an 
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overarching model of late-onset AD with brain amyloid deposition and tau aggregates 
proceeding at different rates, influenced by a combination of protective/risk factors of which 
OSA is part.
51
 This model of AD implies a contributory role of OSA severity in affecting and/or 
accelerating AD biomarker change and possibly increasing neurodegeneration.  In agreement 
with these findings, our previous study performed in the ADNI cohort showed that the presence 
of OSA was associated with accelerated cognitive decline and an earlier age of MCI or AD-
dementia onset.
52
 As expected, there was no difference in the rate-of-biomarker change in the 
AD group by OSA status. This may be because in AD patients, brain amyloid is exhibiting a 
ceiling effect at higher levels of brain atrophy.
53
 OSA’s effect as it relates to AD biomarker 
changes may therefore be attenuated after it has reached its maximum neuronal damage. 
Strengths and Limitations 
Our study possesses several strengths including a well-defined cohort, and objective 
assessment of amyloid burden and CSF P-tau/T-tau, which allowed for a high degree of certainty 
regarding measurement of clinical groups and outcomes.
54
Our statistical analytic methods were 
also robust with respect to unbalanced number of observations per subject over time.  
We acknowledge we were limited by the measurement of OSA by self-report. Self-
reported sleep measures can be impacted by diminished cognition
55
 and in certain situations 
might not be correlated with objective methods.
56
 The prevalence of reported OSA was also 
significantly lower than expected in this elderly cohort, which can relate to an under-diagnosis 
effect in this population, as epidemiological and sleep laboratory studies document much higher 
OSA prevalence in elderly populations. Therefore, some OSA+ subjects were likely 
misclassified into the OSA- group; however, this would have driven our findings towards the 
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null. However, one implication of OSA classification by self-report is that those with self-
reported OSA very likely had associated symptoms (i.e. excessive daytime sleepiness) that 
prompted these subjects to seek diagnosis. The overall prevalence of self-reported OSA in this 
group (6%) is similar to the U.S. prevalence of the OSA Syndrome (OSAS) (4%) defined by the 
presence of AHI4% ≥ 5/hour and daytime symptoms across all ages.57  The prevalence of OSA 
(with or without symptoms) in the elderly is much higher, estimated at 30-50% in older 
subjects,
58
 thus additional work may be required to differentiate the risk of OSA for AD with and 
without associated daytime symptoms. Notably, all-cause excessive daytime sleepiness in elderly 
subjects defined by Epworth sleepiness scores ≥10 was associated with longitudinal brain beta 
amyloid accumulation in a recent study.
59
  
CONCLUSIONS 
OSA appears to accelerate increases in amyloid deposition, CSF T-tau and P-tau levels 
over time, both in NL and MCI individuals. Sleep fragmentation, intermittent hypoxia and 
intrathoracic pressure swings from OSA are likely candidate mechanisms. Thus, clinical 
interventions aimed at OSA, such as treatment with CPAP or dental appliances, in cognitive 
normal and MCI patients, could possibly mitigate or slow the progression of cognitive 
impairment to AD. Further studies examining the mechanisms underlying these observed effects 
are needed. 
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Figure Captions 
Figure 1: Stepwise exclusion process for NL, MCI and AD participants used in the study
 
Figure 2: Mean change variations & Trajectory Plots in AD-biomarker values over time in NL, 
MCI, and AD-subjects by OSA status (Cognitive Normal – NL) 
 
Figure 3: Mean change variations & Trajectory Plots in AD-biomarker values over time in NL, 
MCI, and AD-subjects by OSA status (Mild Cognitive Impairment – MCI) 
 
Figure 4: Mean change variations & Trajectory Plots in AD-biomarker values over time in NL, 
MCI, and AD-subjects by OSA status (Alzheimer’s Disease – AD)
Figure 5: Proposed Mechanisms Linking OSA with Amyloid Deposition in Late-life  
Supplemental Figures1a-c: Baseline AD-Biomarker burden in NL, MCI and AD subjects by 
OSA status
  
Supplemental Figure 2a-c: MANOVA results showing mean change differences in AD-
biomarker values over time by OSA status  
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Table 1: Descriptive Characteristics of Participants by Self-reported Obstructive 
Sleep Apnea Status at Baseline 
 
Cognitive Normal 
Characteristics All OSA- OSA+ 
Number of participants (%) 516 (100) 487 (94) 29 (6) 
Female sex, number (%) 253 (49) 244 (50) 9 (32) 
Age, years, median (interquartile range) 74 (71, 78) 71 (70, 78) 71 (70, 76) 
ApoE4 positive, number (%) 145 (28) 140 (29)  5 (17) 
Education, years, median (interquartile 
range) 
16 (14, 18) 16 (14, 18) 16 (15, 18) 
BMI (kg/m2) 27.2 ± 4.8  27.1 ± 4.7 29.8 ± 5.9  
Hypertension, number (%) 251 (49) 235 (48) 16 (55) 
Diabetes, number (%) 45 (9) 40 (8) 5 (17) 
Thyroid Disease, number (%) 112 (22) 109 (22) 3 (10) 
Respiratory Disease, number (%) 123 (24) 100 (21) 23 (79) 
Cardiovascular Disease, number (%) 358 (69) 338 (69) 20 (69) 
TBI, number (%) 13 (3) 12 (3) 1 (3) 
Alcohol, number (%) 23 (5) 22 (5) 1(3) 
CPAP use 10 (19)  10 (35) 
CSF- Amyloid Beta 42 pg/ml median 
(interquartile range)
 
210 (155, 
241) 
209 (155, 
241) 
226 (199, 
259) 
T-Tau pg/ml median (interquartile range) 59 (45, 84) 59 (45 83) 56 (48, 84) 
P-Tau pg/ml median (interquartile range) 27 (20, 40) 27 (20, 42) 27 (20, 32) 
Florbetapir SUVR, median (interquartile 
range)
s 1.1 (1.0, 1.2) 
1.1 (1.0, 
1.2) 
1.0 (1.0, 1.0) 
MMSE median (interquartile range) 29  (28, 29) 29 (28, 30) 29 (27, 30) 
CDR median (interquartile range) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Mild Cognitive Impairment 
Characteristics All OSA- OSA+ 
Number of participants (%) 798 (100) 695 (87) 103 (13) 
Female sex, number (%) 319 (40) 294 (42) 25 (25) 
Age, years, median (interquartile range) 74 (68, 79) 71 (70, 78) 71 (70, 76) 
ApoE4 positive, number (%) 410 (51) 368 (53)  42 (41) 
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Education, years, median (interquartile 
range) 
16 (14, 18) 16 (14, 18) 16 (14, 18) 
BMI (kg/m2) 26.9 ± 4.6  26.5 ± 4.4 29.4 ± 5.3  
Hypertension, number (%) 395 (49) 337 (48) 58 (56) 
Diabetes, number (%) 75 (9) 57 (8) 18 (17) 
Thyroid Disease, number (%) 156 (20) 133 (19) 23 (22) 
Respiratory Disease, number (%) 195 (24) 133 (19) 62 (60) 
Cardiovascular Disease, number (%) 577 (72) 490 (71) 87 (85) 
TBI, number (%) 18 (2) 14 (2) 4 (4) 
Alcohol, number (%) 35 (4) 31 (5) 4 (4) 
CPAP use 16 (20)  16 (16) 
CSF- Amyloid Beta 42 pg/ml median 
(interquartile range)
s 
153 (130, 
209) 
150 (128, 
206) 
169 (139, 
214) 
T-Tau pg/ml median (interquartile range)
s 
80 (54, 116) 81 (54, 122) 67 (51, 97) 
P-Tau pg/ml median (interquartile range) 36 (23, 51) 37 (23, 52) 32 (21, 44) 
Florbetapir SUVR, median (interquartile 
range)
s 1.2 (1.0, 1.4) 
1.2 (1.0, 
1.4) 
1.1 (1.0, 1.3) 
MMSE median (interquartile range) 27 (24, 28) 28 (25, 29)  26 (25, 28) 
CDR median (interquartile range) 0.5 (0.5, 0.5) 0.5 (0.5,0.5) 0.5 (0.5, 0.5) 
Alzheimer's Disease 
Characteristics All OSA- OSA+ 
Number of participants (%) 325 (100) 303 (93) 22 (7) 
Female sex, number (%) 119 (37) 113 (37) 6 (27) 
Age, years, median (interquartile range) 76 (71, 80) 76 (71, 80) 71 (64, 76) 
ApoE4 positive, number (%) 216 (66) 198 (65)  18 (82) 
Education, years, median (interquartile 
range) 
16 (14, 18) 16 (14, 18) 16 (14, 18) 
BMI (kg/m2) 25.9 ± 4.6  25.6 ± 4.3 29.0 ± 6.8  
Hypertension, number (%) 165 (51) 149 (49) 16 (73) 
Diabetes, number (%) 32 (10) 30 (10) 2 (9) 
Thyroid Disease, number (%) 65 (20) 61 (20)  4 (18) 
Respiratory Disease, number (%) 67 (21) 52 (17) 15 (68) 
Cardiovascular Disease, number (%) 222 (68) 203 (67) 19 (86) 
TBI, number (%) 18 (2) 14 (2) 4 (4) 
Alcohol, number (%) 20 (6) 17 (6) 3 (14) 
CPAP use 9 (3)  9 (41) 
CSF-Amyloid Beta 42 pg/ml median 
(interquartile range)
s 
132 (116, 
151) 
115 (96, 
182) 
113 (79, 
151) 
T-Tau pg/ml median (interquartile range) 80 (54, 116) 67 (51, 97) 81 (54, 122) 
P-Tau pg/ml median (interquartile range) 42 (33, 61) 41 (33, 61) 54 (35, 66) 
Florbetapir SUVR, median (interquartile 
range) 
1.4 (1.3, 1.5) 
1.4 (1.3, 
1.5) 
1.4 (1.3, 1.6) 
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MMSE median (interquartile range) 24 (20, 26) 24 (22, 26) 24 (20, 25) 
CDR median (interquartile range) 2.0 (1.0, 2.5) 1.5 (1.0,2.5) 2.0 (1.0, 2.5) 
Abbreviation: Aβ: amyloid beta, ApoE4: Apolipoprotein epsilon4, BMI: body mass index, CDR: Clinical Dementia Rating; 
CPAP: continuous pulmonary airway pressure; CSF: cerebrospinal fluid, MMSE: Mini Mental State Exam; TAU: tau protein, 
PTAU: phosphorylated tau, TBI: traumatic brain injury. Superscript s: indicates significant differences between groups (CSF 
Aβ42 levels for both MCI (F=4.37, p=.04), and AD (F=6.89, p<.01 and T-tau levels for the MCI patients (F=5.08, p=.02) 
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Table 2: Multivariate ANOVA Results Testing Biomarker Mean Change Differences in Time Trend, Groups and Time 
Points 
 
 
MANOVA Test 
Criteria Statistic Value 
F-
value P-value 
MANOVA Test 
Criteria Statistic Value 
F-
value P-value 
Florbetapir SUVR CSF Aβ42 
Normal Cognition (NL) Normal Cognition (NL) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.035 4.46 0.0125* 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.122 5.23 0.0075** 
Timepoint Effect 
Pillai's 
Trace 0.162 23.66 <.0001*** Timepoint Effect 
Pillai's 
Trace 0.579 51.77 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
0.14 0.7125 Timepoint_1 (Year 2) 
  
9.99 0.0023** 
timepoint_2 (Year 3) 8.93 0.0031** timepoint_2 (Year 3) 4.12 0.046* 
timepoint_1 vs. 
timepoint_0 34.22 <.0001*** 
timepoint_1 vs. 
timepoint_0 69.4 <.0001*** 
timepoint_2 vs. 
timepoint_1 6.51 0.0113* 
timepoint_2 vs. 
timepoint_1 8.08 0.0006*** 
  
Mild Cognitive Impairment (MCI) Mild Cognitive Impairment (MCI) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.047 4.24 0.0143* 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.219 5.06 0.0116* 
Timepoint Effect 
Pillai's 
Trace 0.129 18.06 <.0001*** Timepoint Effect 
Pillai's 
Trace 0.791 68.23 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
0.08 0.7786 Timepoint_1 (Year 2) 
  
4.95 0.0323* 
timepoint_2 (Year 3) 4.63 0.0323* timepoint_2 (Year 3) 7.38 0.01* 
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timepoint_1 vs. 
timepoint_0 25.63 <.0001*** 
timepoint_1 vs. 
timepoint_0 132.92 <.0001*** 
timepoint_2 vs. 
timepoint_1 6.16 0.0137* 
timepoint_2 vs. 
timepoint_1 13.12 0.0009*** 
  
Alzheimer's Disease (AD) Alzheimer's Disease (AD) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.016 1.94 0.1457 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.092 2.48 0.0944 
Timepoint Effect 
Pillai's 
Trace 0.207 31.86 <.0001*** Timepoint Effect 
Pillai's 
Trace 0.933 341.26 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
0.64 0.4228 Timepoint_1 (Year 2) 
  
3.78 0.0575 
timepoint_2 (Year 3) 3.39 0.067 timepoint_2 (Year 3) 1.16 0.2873 
timepoint_1 vs. 
timepoint_0 3.39 0.067 
timepoint_1 vs. 
timepoint_0 1.16 0.2873 
timepoint_2 vs. 
timepoint_1 0.55 0.4593 
timepoint_2 vs. 
timepoint_1 0.12 0.7253 
  
CSF TAU CSF PTAU 
Normal Cognition (NL) Normal Cognition (NL) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.096 3.99 0.0226* 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.142 4.06 0.0235* 
Timepoint Effect 
Pillai's 
Trace 0.302 16.24 <.0001*** Timepoint Effect 
Pillai's 
Trace 0.545 29.29 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
3.1 0.083 Timepoint_1 (Year 2) 
  
5.74 0.0204* 
timepoint_2 (Year 3) 8.04 0.0006*** timepoint_2 (Year 3) 5.74 0.0203* 
timepoint_1 vs. 32.9 <.0001*** timepoint_1 vs. 53.39 <.0001*** 
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timepoint_0 timepoint_0 
timepoint_2 vs. 
timepoint_1 17.34 <.0001*** 
timepoint_2 vs. 
timepoint_1 3.64 0.0621 
  
Mild Cognitive Impairment (MCI) Mild Cognitive Impairment (MCI) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.198 4.44 0.0189* 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.272 6.73 0.0033** 
Timepoint Effect 
Pillai's 
Trace 0.321 8.46 0.001** Timepoint Effect 
Pillai's 
Trace 0.762 57.72 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
1.13 0.2957 Timepoint_1 (Year 2) 
  
12.72 0.0001*** 
timepoint_2 (Year 3) 9.1 0.0046** timepoint_2 (Year 3) 4.2 0.0474* 
timepoint_1 vs. 
timepoint_0 17.39 0.0002*** 
timepoint_1 vs. 
timepoint_0 62.45 <.0001*** 
timepoint_2 vs. 
timepoint_1 12.9 0.001** 
timepoint_2 vs. 
timepoint_1 3.89 0.056 
  
Alzheimer's Disease (AD) Alzheimer's Disease (AD) 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.114 4.83 0.0106* 
Timepoint*OSA 
Effect 
Pillai's 
Trace 0.074 1.63 0.2086 
Timepoint Effect 
Pillai's 
Trace 0.751 112.37 <.0001*** Timepoint Effect 
Pillai's 
Trace 0.939 312.8 <.0001*** 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- 
Timepoint_1 (Year 2) 
  
3.42 0.0684 Timepoint_1 (Year 2) 
  
3.23 0.0797 
timepoint_2 (Year 3) 8.68 0.0043** timepoint_2 (Year 3) 0.09 0.7622 
timepoint_1 vs. 
timepoint_0 8.68 0.0043** 
timepoint_1 vs. 
timepoint_0 0.09 0.7622 
timepoint_2 vs. 0.52 0.4712 timepoint_2 vs. 2.24 0.1423 
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timepoint_1 timepoint_1 
 
SUVR: Standard Uptake Value Ratio of Brain Florbetapir; CSF: Cerebrospinal fluid; PTAU: phosphorylated TAU. MANOVA: Multivariate Analysis of Variance.  MANOVA test 
criteria interpretations: Timepoint*OSA Effect provides the exact F statistics for the time trend of mean change in Alzheimer's disease biomarker across OSA groups; Timepoint 
Effect provides the exact F statistics for the mean change (increase or decrease) in Alzheimer's disease biomarker over time. Repeated Measures Analysis of Variance of Contrast 
Variables OSA+ vs. OSA- interpretations: Timepoint_1 (Year 2) provides the F statistic for the difference in mean change in Alzheimer's disease biomarker across OSA groups 
from baseline (Year 1) to Year 2; Timepoint_2 (Year 3) provides the F statistic for the difference in mean change in Alzheimer's disease biomarker across OSA groups from 
baseline (Year 1) to Year 3.; timepoint_1 vs. timepoint_0 provides the F statistic for differences in mean change in Alzheimer's disease biomarker across OSA groups when 
timepoint 1 (Year 2) is compared to baseline (Year 1);  timepoint_2 vs. timepoint_1 provides the F statistic for differences in mean change in Alzheimer's disease biomarker across 
OSA groups when timepoint 2 (Year 3) is compared to timepoint 1 (Year 2). *P-value <=.05; **P-value <=.01; ***P-value<=.001 
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Table 3 Between Subject Variation in AD Biomarkers and Covariance Parameter 
Estimates 
 
Parameters Estimate 95% CI 
P-
value 
OSA+ vs. OSA-  (Cognitive Normal Patients) 
Florbetapir SUVR over time  0.06 .02, .11 <.0001 
Florbetapir SUVR over time (covariance) -0.06 -.09, -.04 <.0001 
CSF Aβ-42 over time  -2.71 -3.11, -2.35 <.0001 
CSF Aβ-42 over time (covariance) 3.93 3.56 , 4.31 <.0001 
CSF TTAU over time  3.68 3.31 , 4.07 <.0001 
CSF TTAU over time (covariance) -2.89 -3.51, -2.29 <.0001 
CSF PTAU over time  1.22 1.02 , 1.42 <.0001 
CSF PTAU over time (covariance) -1.21 -1.71, - .74 <.0001 
OSA+ vs. OSA- (Mild Cognitive Impairment Patients) 
Florbetapir SUVR over time  0.08 .05, .12 <.0001 
Florbetapir SUVR over time (covariance) -0.06 -.09, -.04 <.0001 
CSF Aβ-42 over time  -2.62 -3.23, -2.03 <.0001 
CSF Aβ-42 over time (covariance) 2.69 2.02, 3.36 <.0001 
CSF TAU volume over time  2.21 1.58, 2.86 <.0001 
CSF TAU over time (covariance) -1.89 -2.91, -.87 <.0001 
CSF PTAU over time  1.74 1.22, 2.27 <.0001 
CSF PTAU over time (covariance) -1.48 -2.05, -.94 <.0001 
OSA+ vs. OSA- (Alzheimer's disease Patients) 
Florbetapir SUVR over time  0.07 -1.19, 1.33 0.33 
Florbetapir SUVR over time (covariance) -0.29 -2.07, 1.49 0.31 
CSF Aβ-42 over time  -1.11 -3,31, 1.09 0.53 
CSF Aβ-42 over time (covariance) -1.14 -3.38, 1.63  0.56 
CSF TTAU over time  0.26 -1.02, 1,28 0.47 
CSF TTAU over time (covariance) -0.15 -1.94, 1.64 0.47 
CSF PTAU over time  0.94 0.23, 1.65 0.11 
CSF PTAU over time (covariance) -0.16 -1.66, 1.34 0.11 
These analyses allowed us to examine whether there was significant variation between OSA+ and OSA- subjects in mean AD 
biomarker level at baseline, as well as whether significant variation in the change in AD biomarker level over time occurred. 
Furthermore, the covariance between the baseline AD biomarker level and AD biomarker change over time indicated whether 
OSA+ or OSA- subjects had experienced a faster increase or decrease in AD biomarker level over time. It also allowed for 
assessment of significant differences in the rate-of-change in AD biomarker level between OSA groups over time. 
Abbreviations: Aβ: amyloid beta, ApoE4: Apolipoprotein epsilon4, BMI: body mass index, CSF: cerebrospinal fluid, TAU: tau 
protein, PTAU: phosphorylated tau. Models were adjusted for age, sex, BMI, education, CPAP-use, ApoE4 status, alcohol intake, 
baseline biomarker data, history of respiratory disease, hypertension, diabetes and history of cardiovascular disease (e.g. 
including ischemic heart disease, heart failure, and stroke/TIA), and history of traumatic brain injury
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